Update, November 12, 2026
Since the November 3 report, ELV has edged higher, up about 1.0% on the day and 0.43% over the past five sessions, while the broader market (SPY) rose 3.69% and the health‑care sector ETF (XLV) gained 2.23% in the same period, indicating the stock’s modest move is largely in line with sector strength rather than a market‑wide rally.
The picture holds – ELV remains above the swing‑zone support at 427.08 and the daily close is still shy of the 52‑week high breakout level of 445.28, so the upside target of 449.62 and the stop at 423.76 are unchanged. The 50‑day SMA at 415.18 continues to sit well below price, and volume is still muted at roughly 75% of its 20‑day average, keeping the current structure intact. A weekly close below the swing‑zone (around 407.67) would be the trigger that could change the picture.
Recent disclosures include a Regulation FD filing on SEC EDGAR (Nov 10) and the Q3 2026 earnings release (Oct 21), which showed modest revenue growth and a 15% rise in net income, supporting the continued bullish bias.
Elevance Health (ELV) raised its 2026 guidance with third-quarter results on October 21, 2026, and the shares have since given back much of the rally, trading at $412.49, 7.4% below the October 22 peak. The balance of evidence still leans positive, with medium conviction: the weekly uptrend is intact and the stock sits on its 50-day average. The breakout math from here does not reach 3 to 1.
Why it matters
The quarter was one of steady earnings rather than fast growth. Operating revenue was $50.4 billion, up 0.7% from $50.1 billion a year earlier, and the company raised its full-year 2026 guidance, according to the 8-K. The quarterly filing shows revenue of $51.43 billion, up 1%, net income of $1.36 billion, up 15%, and diluted earnings per share of $6.27, per the 10-Q. Adjusted EPS was $6.99, and that figure includes a net non-operating benefit of $1.85 per share. The headline growth came from profit and guidance, not from sales.
The market paid up for that news at first. ELV closed at $445.28 on October 22, its 52-week high, the day after the report. Since then the stock has fallen 7.4%, including 2.1% over the last five days. Today's volume is running 67.3% below its 20-day average, so the pullback looks quiet rather than forced. The news does not explain this drop; no new company event has followed the earnings release.
Most of the five-day slide came from the market. SPY fell 2.1% over the same five days, almost exactly matching ELV's 2.1% decline. The healthcare sector went the other way: XLV gained 2.8%, so ELV trailed its sector by 5.0 points. The gap shows up over longer spans too. ELV is up 6.7% over one month against 10.9% for XLV, and it trails the sector by 6.0% over 50 days while leading the S&P 500 by 2.1% over the same stretch. So ELV fell with the market and missed the sector's rebound.
No outside commentary on ELV was in the record, so the two sides of the argument come from the filings themselves. The constructive side is a guidance raise, net income up 15% and a Wall Street consensus of buy from 21 analysts. The cautious side is revenue growth of about 1% and adjusted earnings that lean on a $1.85 non-operating benefit, which makes the quality of the beat the real question. On valuation, the mean price target is $482.38, with a range from $406 to $523. The stock sits 14.5% below the mean, and even the lowest target is only just under today's price.
What the evidence says
The long-term thesis is intact. The price is above its 40-week average and well above the 200-day average at $372.70. It is 46.9% above its 52-week low of $280.74 and up 17.7% for the year, against 10.5% for SPY. The stock is in a pullback inside an uptrend, not a reversal. The shares are below their 10-week average, and the RSI of 39.95 is weak but not oversold.
Over the next 2 to 6 weeks the balance of evidence leans positive, with medium conviction: 2 of 4 points. The daily trend runs with the weekly uptrend, and ELV leads the S&P 500 over 50 days. Against that, it lags its sector over the same period, and that is why conviction is not higher.
The strongest case against the positive reading is that money is moving into healthcare but not into ELV. The stock lost 5.0 points to the sector in five days, trails it by 6.0% over 50 days, and has slipped under its 10-week average. If the sector keeps rising without ELV, the post-earnings peak of $445.28 may mark a lasting top. It does not tip the balance because the weekly uptrend is intact, the 50-day average is still holding, and the selling has come on very light volume.
Levels that matter
The structure holds above $411.02, the 50-day average, and the stock is sitting almost on it. A move under that line would be the first crack. The trend ends below $407.67, a swing zone, and below it the next supports are $400.00 (round), $391.10 and $382.85.
The breakout level is a daily close above $425.00 (round) on volume above its 20-day average. From there the first target is $427.08, a swing zone just above the level, which gives only 0.1 to 1. The second is the 52-week high of $445.28, which gives 1.2 to 1. The stop sits at $408.02, which is the 50-day average minus a quarter of the 14-day ATR of $12.00. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well beyond the 52-week high, or a stop much closer to the entry, to change that. A close above $450.00 would be the next round-number test.
What would change the picture
A weekly close below $407.67 would end the case for the uptrend and turn the picture negative. The non-price fact that would most likely do it is a guidance cut, or evidence that medical costs are running above what the raised 2026 outlook assumed. That would undercut the thesis that this quarter's improvement is lasting.
What to watch
- Next earnings, January 28, 2027: the number that matters is adjusted EPS excluding non-operating items, set against the $6.99 reported this quarter. Operating earnings need to carry the result.
- Sector events: peer results and policy news on Medicare Advantage and Medicaid can move ELV before its own report. XLV is rising, and ELV has not kept pace.
- Valuation: the stock is 14.5% below the $482.38 mean target. The low target of $406 is close to today's price, and the high is $523.